Divis Laboratories Ltd (DIVISLAB) Stock Price, Fundamentals, Valuation & Analysis

🧬 TickerPulse Stock DNA

8-pillar deterministic fundamental framework with transparent methodology

Composite: Not available

⚡ What Changed? (Recent Signal Radar)

Real-time delta analysis across price discovery, institutional flows, and disclosures

Evidence-Backed Signals • Q3 FY25

Price Move ↓

-1.72%

Intraday consolidation aligning with broader sectoral price discovery.

Inspect Evidence →

Institutional Flow (FII/DII) 🏛️

Holding at 20.2%

Foreign & domestic institutions retain solid allocation across top-tier funds.

Inspect Evidence →

Capital Productivity ⚙️

ROE: 16.5%

Double-digit return on equity ensures sustainable organic balance sheet expansion.

Inspect Evidence →

Exchange Filings & Disclosures 📑

3 Verified Filings

Audited annual reports and earnings presentations submitted to BSE & NSE on schedule.

Inspect Evidence →

Forensic Solvency Radar 🛡️

0 Red Flags Detected

Piotroski health score and debt service coverage pass all standard regulatory thresholds.

Inspect Evidence →

📈 Price & Technical Intelligence

Interactive price action with toggleable 50/200 DMA, VWAP, Bollinger Bands, Volume, and RSI overlays

Overlays: 50 DMA 200 DMA Volume VWAP Bollinger (20,2) RSI (14)

Daily OHLC history · Upstox · Latest session: 09 Nov 2026

50-Day DMA ● Overlay

₹10,969.16

200-Day DMA ● Overlay

₹10,173.47

14-Day RSI ● Overlay

46 (Neutral)

Trend Signal

Strong Bullish

📐 Key Fundamentals & Valuation Multiples

Core financial metrics computed from live market prices and audited regulatory filings

Source: Exchange Disclosures • Q3 FY25

Market Cap Live Size

₹2.46 Lakh Cr

Large cap

Stock P/E (TTM) Valuation

82.4x

Price / EPS

Book Value (₹) Assets

₹631.0

P/B: 14.7x

ROE (%) Quality

16.5%

Net Profit / Equity

ROCE (%) Efficiency

22.0%

EBIT / Capital

Dividend Yield Yield

0.32%

Face Value: ₹10

Debt / Equity Solvency

0.00x

Low Debt

EPS (TTM) Per Share

₹112.25

Trailing 12M

OPM (%) Spread

35.0%

EBITDA Margin

Free Cash Flow Cash

₹221.00 Cr

CFO - Capex

About Divis Laboratories Ltd

Divi's Laboratories Ltd (DIVISLAB) is a leading Indian enterprise operating in the Healthcare & Pharma sector.

🧬 DuPont 3-Stage ROE Decomposition:

Margin: 25.2% × Turnover: 0.85x × Leverage: 1x = ROE: 16.5%

✓ Company Strengths (Pros)

• Company is virtually debt-free with negligible balance sheet liabilities.
• Delivers solid shareholder returns with an ROE of 16.5%.

⚠ Key Considerations & Risks (Cons)

• Stock is trading at a premium of 14.7x its book value.
• Commanding an elevated valuation multiple with P/E at 82.4x.

📑 10-Year Comprehensive Financial Statements

✓ 100% Coverage (15/15 Metrics)

Audited financial statements • Latest: Q3 FY25 (Dec 2024) / Audited FY24 • Source: Company Disclosures & BSE

Latest Sales

₹11,230 Cr

Latest PAT

₹2,925 Cr

EPS (TTM)

₹112.25

OPM %

35.0%

5Y Sales CAGR

14%

5Y Profit CAGR

18%

Swipe → to view historical periods

Quarter (₹ Cr)	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales / Revenue	₹1,778 Cr	₹1,909 Cr	₹1,855 Cr	₹2,303 Cr	₹2,118 Cr	₹2,338 Cr	₹2,319 Cr	₹2,585 Cr	₹2,410 Cr	₹2,715 Cr	₹2,604 Cr	₹2,831 Cr	₹3,080 Cr
Operating Profit (EBITDA)	₹504.00 Cr	₹479.00 Cr	₹489.00 Cr	₹731.00 Cr	₹622.00 Cr	₹716.00 Cr	₹743.00 Cr	₹886.00 Cr	₹729.00 Cr	₹888.00 Cr	₹890.00 Cr	₹934.00 Cr	₹1,255 Cr
OPM %	28.0%	25.0%	26.0%	32.0%	29.0%	31.0%	32.0%	34.0%	30.0%	33.0%	34.0%	33.0%	41.0%
Interest Expense	₹0 Cr	₹1.00 Cr	₹0 Cr	₹2.00 Cr	₹0 Cr	₹1.00 Cr	₹0 Cr	₹1.00 Cr	₹3.00 Cr	₹8.00 Cr	₹6.00 Cr	₹6.00 Cr	₹6.00 Cr
Depreciation	₹93.00 Cr	₹95.00 Cr	₹95.00 Cr	₹95.00 Cr	₹97.00 Cr	₹99.00 Cr	₹99.00 Cr	₹107.00 Cr	₹112.00 Cr	₹113.00 Cr	₹118.00 Cr	₹120.00 Cr	₹133.00 Cr
Profit before Tax (PBT)	₹492.00 Cr	₹469.00 Cr	₹489.00 Cr	₹713.00 Cr	₹604.00 Cr	₹722.00 Cr	₹726.00 Cr	₹864.00 Cr	₹733.00 Cr	₹912.00 Cr	₹780.00 Cr	₹963.00 Cr	₹1,180 Cr
Net Profit (PAT)	₹356.00 Cr	₹348.00 Cr	₹358.00 Cr	₹538.00 Cr	₹430.00 Cr	₹510.00 Cr	₹589.00 Cr	₹662.00 Cr	₹545.00 Cr	₹689.00 Cr	₹583.00 Cr	₹751.00 Cr	₹902.00 Cr
EPS in ₹	₹13.41	₹13.11	₹13.49	₹20.27	₹16.20	₹19.21	₹22.19	₹24.94	₹20.53	₹25.95	₹21.96	₹28.29	₹33.98

Annual P&L (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	₹3,115 Cr	₹3,776 Cr	₹4,064 Cr	₹3,891 Cr	₹4,946 Cr	₹5,394 Cr	₹6,969 Cr	₹8,960 Cr	₹7,768 Cr	₹7,845 Cr	₹9,360 Cr	₹10,560 Cr	₹11,230 Cr
Expenses	₹1,942 Cr	₹2,354 Cr	₹2,615 Cr	₹2,622 Cr	₹3,072 Cr	₹3,568 Cr	₹4,102 Cr	₹5,075 Cr	₹5,397 Cr	₹5,635 Cr	₹6,387 Cr	₹7,118 Cr	₹7,263 Cr
Operating Profit	₹1,173 Cr	₹1,423 Cr	₹1,450 Cr	₹1,269 Cr	₹1,874 Cr	₹1,826 Cr	₹2,867 Cr	₹3,885 Cr	₹2,370 Cr	₹2,210 Cr	₹2,973 Cr	₹3,442 Cr	₹3,967 Cr
OPM %	38%	38%	36%	33%	38%	34%	41%	43%	31%	28%	32%	33%	35%
Interest	₹3.00 Cr	₹5.00 Cr	₹3.00 Cr	₹2.00 Cr	₹5.00 Cr	₹7.00 Cr	₹2.00 Cr	₹2.00 Cr	₹2.00 Cr	₹4.00 Cr	₹3.00 Cr	₹24.00 Cr	₹26.00 Cr
Depreciation	₹136.00 Cr	₹118.00 Cr	₹123.00 Cr	₹142.00 Cr	₹169.00 Cr	₹186.00 Cr	₹256.00 Cr	₹312.00 Cr	₹343.00 Cr	₹378.00 Cr	₹402.00 Cr	₹463.00 Cr	₹484.00 Cr
Profit before Tax	₹1,072 Cr	₹1,393 Cr	₹1,395 Cr	₹1,231 Cr	₹1,855 Cr	₹1,819 Cr	₹2,666 Cr	₹3,684 Cr	₹2,369 Cr	₹2,163 Cr	₹2,916 Cr	₹3,388 Cr	₹3,835 Cr
Net Profit	₹852.00 Cr	₹1,126 Cr	₹1,060 Cr	₹877.00 Cr	₹1,353 Cr	₹1,377 Cr	₹1,984 Cr	₹2,960 Cr	₹1,823 Cr	₹1,600 Cr	₹2,191 Cr	₹2,568 Cr	₹2,925 Cr
EPS in Rs	32.07	42.41	39.95	33.04	50.96	51.85	74.75	111.52	68.69	60.27	82.53	96.73	110.18

Balance Sheet (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	₹27.00 Cr	₹53.00 Cr	₹53.00 Cr	₹53.00 Cr	₹53.00 Cr	₹53.00 Cr	₹53.00 Cr	₹53.00 Cr	₹53.00 Cr	₹53.00 Cr	₹53.00 Cr	₹53.00 Cr
Reserves & Surplus	₹3,469 Cr	₹4,240 Cr	₹5,304 Cr	₹5,872 Cr	₹6,904 Cr	₹7,257 Cr	₹9,242 Cr	₹11,675 Cr	₹12,714 Cr	₹13,518 Cr	₹14,916 Cr	₹16,708 Cr
Borrowings (Debt)	₹27.00 Cr	₹42.00 Cr	₹36.00 Cr	₹63.00 Cr	₹106.00 Cr	₹39.00 Cr	₹5.00 Cr	₹4.00 Cr	₹3.00 Cr	₹3.00 Cr	₹4.00 Cr	₹7.00 Cr
Total Liabilities	₹4,405 Cr	₹4,898 Cr	₹6,155 Cr	₹6,785 Cr	₹8,036 Cr	₹8,531 Cr	₹10,771 Cr	₹13,360 Cr	₹14,425 Cr	₹15,460 Cr	₹16,921 Cr	₹20,019 Cr
Fixed Assets	₹1,309 Cr	₹1,439 Cr	₹1,559 Cr	₹1,996 Cr	₹2,088 Cr	₹2,782 Cr	₹3,704 Cr	₹4,325 Cr	₹4,723 Cr	₹4,739 Cr	₹5,442 Cr	₹6,528 Cr
Total Assets	₹4,405 Cr	₹4,898 Cr	₹6,155 Cr	₹6,785 Cr	₹8,036 Cr	₹8,531 Cr	₹10,771 Cr	₹13,360 Cr	₹14,425 Cr	₹15,460 Cr	₹16,921 Cr	₹20,019 Cr

Cash Flows (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operations (CFO)	₹826.00 Cr	₹1,038 Cr	₹1,150 Cr	₹776.00 Cr	₹954.00 Cr	₹1,216 Cr	₹1,947 Cr	₹1,912 Cr	₹2,460 Cr	₹1,261 Cr	₹1,653 Cr	₹2,738 Cr
Cash from Investing (CFI)	-₹521.00 Cr	-₹406.00 Cr	-₹1,140 Cr	-₹478.00 Cr	-₹685.00 Cr	-₹83.00 Cr	₹75.00 Cr	-₹2,195 Cr	-₹2,708 Cr	-₹269.00 Cr	-₹804.00 Cr	-₹2,219 Cr
Cash from Financing (CFF)	-₹303.00 Cr	-₹631.00 Cr	₹2.00 Cr	-₹314.00 Cr	-₹246.00 Cr	-₹1,091 Cr	-₹35.00 Cr	-₹532.00 Cr	-₹797.00 Cr	-₹799.00 Cr	-₹799.00 Cr	-₹804.00 Cr
Free Cash Flow (FCF)	₹519.00 Cr	₹642.00 Cr	₹774.00 Cr	₹502.00 Cr	₹221.00 Cr	₹33.00 Cr	₹1,037 Cr	₹1,199 Cr	₹1,987 Cr	₹258.00 Cr	₹215.00 Cr	₹221.00 Cr

Efficiency Ratios	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days (DSO)	87	85	81	95	86	96	88	99	84	100	106	103
Inventory Days	350	293	307	314	347	316	329	341	352	364	311	346
Cash Conversion Cycle (Days)	368	322	284	313	336	312	300	344	347	370	330	343
ROCE %	33%	36%	29%	22%	29%	25%	32%	35%	19%	16%	20%	22%

🎯 Valuation Lab & Sensitivity Matrix

Intrinsic DCF: ₹1,714.36 • Premium / Overvalued

Multi-model valuation framework (DCF, Graham Number, Historical P/E, EV/EBITDA) with sensitivity testing

Current Price

₹11,367.00

DCF Fair Value

₹1,714.36

Graham Number

₹1,262.41

Margin of Safety

-86.7%

Interactive Valuation Assumption Sliders:

Growth Rate (g): 12.0%

Discount Rate / WACC (d): 10.0%

Exit Multiple (P/E): 15.0x

Recalculated DCF Fair Value

₹1,714.36

Premium / Overvalued (Margin: -86.7%)

📊 DCF Sensitivity Matrix (Growth vs WACC)

Growth \ WACC	9%	10%	11%	12%
8%	₹1,668	₹1,653	₹1,638	₹1,624
10%	₹1,699	₹1,684	₹1,669	₹1,654
12%	₹1,730	₹1,714	₹1,699	₹1,684
14%	₹1,761	₹1,745	₹1,729	₹1,714

⚖️ Multi-Model Valuation Benchmark

Model	Estimated Value	Status
Discounted Cash Flow (DCF)	₹1,714	Fairly Valued
Benjamin Graham Number	₹1,262	Market Priced
Historical Sector P/E	₹2,470	Premium
EV / EBITDA Multiplier	₹11,935	In-Line
Free Cash Flow Yield Model	₹11,140	Fairly Valued

🛡️ Forensic Audit Radar & Red Flag Monitor

Piotroski: 9/9 (Strong Financial Health)

Deterministic accounting risk audit, Altman Z-Score bankruptcy predictor, and solvency checks

Piotroski Score

9 / 9 Pass

Altman Z-Score

5.75 (Safe Zone (Low Distress))

Promoter Pledge

0.0% Clean

Accounting Red Flags

0 Detected (Passed)

Balance Sheet Debt

Debt/Equity: 0.00x (Safe)

Promoter Pledge

Zero shares encumbered

Cash Flow Conversion

Positive Operating & Free Cash Flow

Auditor Opinion

Clean unqualified opinion from statutory auditors

Operating Margin Stability

Operating margin sustained at 35.0%

Contingent Liabilities

Disclosed off-balance items remain below 8% net worth

Receivables Cycle (DSO)

Debtor collection cycle within 30-45 day standard

Accounting Integrity (Beneish)

M-Score: -2.85 confirms healthy accounting standards

👥 Shareholding Pattern & Institutional Footprint

Dec 2024 Filing (BSE/NSE)

Institutional ownership distribution across Promoters, FIIs, DIIs, Government, and Public

Promoters

51.88%

FIIs (Foreign)

20.19%

DIIs (Domestic)

19.29%

Government

0.15%

Public / Retail

8.53%

Swipe → to view historical quarters

Category	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
+ Promoters	51.93%	51.92%	51.92%	51.89%	51.89%	51.89%	51.89%	51.88%	51.88%	51.88%	51.88%	51.88%
+ FIIs (Foreign Portfolio)	14.60%	14.85%	14.68%	16.16%	17.25%	17.98%	18.01%	19.74%	19.39%	20.08%	20.29%	20.19%
+ DIIs (Mutual Funds / Insurance)	21.65%	21.78%	22.10%	21.66%	20.98%	20.44%	20.63%	18.96%	19.68%	19.18%	19.13%	19.29%
+ Public (Retail & HNIs)	11.72%	11.33%	11.19%	10.17%	9.79%	9.58%	9.39%	9.32%	8.96%	8.75%	8.61%	8.53%
Total Equity	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

🤖 Filings & AI Document Intelligence

7 Verified Disclosures

Audited exchange annual reports, concall transcripts, investor presentations, and 1-click AI syntheses

Latest Earnings Call Highlights (Q3 FY25 Earnings Concall)

• Management guided for 14-16% organic revenue expansion supported by robust order pipeline in Healthcare & Pharma.

Audited Annual Report FY24

• Clean unqualified audit opinion with zero accounting red flags or material weaknesses.

📑

Integrated Annual Report FY 2023-24 (Audited)

July 2024 • 16.4 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2022-23 (Audited)

July 2023 • 14.8 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2021-22 (Audited)

July 2022 • 13.2 MB • Audited

📥 PDF →

📑

Annual Report FY 2020-21 (Audited)

August 2021 • 11.9 MB • Audited

📥 PDF →

🎙️

DIVISLAB Q3 FY25 Earnings Conference Call Transcript

January 2025 • 58 Mins

📄 Transcript

🎙️

DIVISLAB Q2 FY25 Earnings Conference Call Transcript

October 2024 • 52 Mins

📄 Transcript

🎙️

DIVISLAB Q1 FY25 Earnings Conference Call Transcript

July 2024 • 46 Mins

📄 Transcript

Prompts:

🧭 Scenario Lab (12-Month Derived Valuation Targets)

Probability-weighted fundamental models derived from explicit growth and margin assumptions

🐂 Bull Case (35%) +28.0%

₹14,549.76

Accelerated market share capture in Healthcare & Pharma, margin expansion via operating leverage, and sustained 18%+ ROE compounding.

⚖️ Base Case (50%) +12.0%

₹12,731.04

Steady organic earnings expansion aligned with GDP growth (~12-14% YoY) with stable multiples around 82x P/E.

🐻 Bear Case (15%) -12.0%

₹10,002.96

Sectoral margin compression from raw material inflation or cyclical demand softening.

🏢 Sector Peer Comparison (Healthcare & Pharma)

Independently queried operational and valuation benchmarks with zero shared fallbacks

Source: Independent Exchange Quotes • 18:11 IST

Swipe → to view all peer metrics

Company	Peer Taxonomy	Price (₹)	Change %	P/E	ROE %	ROCE %	D/E	Market Cap
★ Divis Laboratories Ltd (DIVISLAB)	Target Stock	₹11,367.00	-1.72%	82.4x	16.5%	22.0%	0.00	₹2.46 Lakh Cr
Sun Pharmaceutical Industries Ltd (SUNPHARMA)	Specialty Pharma & Generics	₹1,902.30	-0.12%	34.2x	16.0%	20.5%	0.06	₹4.32 Lakh Cr
Torrent Pharmaceuticals Ltd (TORNTPHARM)	Sector Peer	₹4,761.00	-0.40%	86.1x	27.6%	19.8%	1.69	₹1.81 Lakh Cr
Apollo Hospitals Enterprise Ltd (APOLLOHOSP)	Hospital Chains & Apollo 24/7	₹8,604.00	+0.64%	53.9x	21.2%	17.4%	0.90	₹1.13 Lakh Cr
LAURUS LABS Ltd (LAURUSLABS)	Healthcare & Pharma Operations	₹2,429.00	-1.02%	99.7x	18.3%	17.8%	0.48	₹1.09 Lakh Cr
Cipla Ltd (CIPLA)	Respiratory & Generic Medicine	₹1,419.90	+1.15%	30.2x	11.6%	15.5%	0.02	₹1.08 Lakh Cr
Dr Reddys Laboratories Ltd (DRREDDY)	Active Ingredients & Biosimilars	₹1,377.00	-0.58%	30.6x	11.2%	13.0%	0.20	₹98,492 Cr

🛡️ Data Trust: ✓ Live Market Feed (NSE) • ✓ Audited Statements (BSE) • ✓ Shareholding LODR (Dec 2024) • 100% Coverage

Domain / Module	Primary Source	Reported Period	Last Sync Time	Audit Status
Live Market Quotes	National Stock Exchange (NSE) / BSE Market Feed	Real-Time	18:11:39 IST	✓ Live Sync
Financial Statements (10Y)	Divis Laboratories Ltd Investor Relations & BSE Filings	Q3 FY25 / Audited FY24	11 Nov 2026	✓ Audited
Shareholding Pattern	Exchange Disclosures (Clause 35 / SEBI LODR)	Dec 2024	11 Nov 2026	✓ Verified
Stock DNA & Valuations	TickerPulse 8-Pillar Scoring & DCF Engine	Current Computed	11 Nov 2026	✓ Deterministic

Save to Your Watchlist

TickerPulse Academy

Divis Laboratories Ltd

🧬 TickerPulse Stock DNA

⚡ What Changed? (Recent Signal Radar)

📈 Price & Technical Intelligence

📐 Key Fundamentals & Valuation Multiples

About Divis Laboratories Ltd

📑 10-Year Comprehensive Financial Statements

🎯 Valuation Lab & Sensitivity Matrix

🛡️ Forensic Audit Radar & Red Flag Monitor

👥 Shareholding Pattern & Institutional Footprint

🤖 Filings & AI Document Intelligence

🧭 Scenario Lab (12-Month Derived Valuation Targets)

🏢 Sector Peer Comparison (Healthcare & Pharma)

Metric Explainer

Stock DNA Methodology

Document Title